HEPION PHARMACEUTICALS, INC. Restructuring Costs
HEPION PHARMACEUTICALS, INC. (HEPA) reported Restructuring Costs of $100.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-04-08.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:RestructuringCosts · last filed 2025-04-08
- HEPION PHARMACEUTICALS, INC. restructuring costs for the quarter ending 2023-12-31 was $700.00K.
- HEPION PHARMACEUTICALS, INC. restructuring costs for fiscal 2024 was $100.00K, a 85.71% decline from fiscal 2023.
- HEPION PHARMACEUTICALS, INC. restructuring costs for fiscal 2023 was $700.00K.
| Period end | Restructuring Costs 3 month | Restructuring Costs 6 month | Restructuring Costs 12 month |
|---|---|---|---|
| 2024-12-31 | $100.00K 10-K · filed 2025-04-08 | ||
| 2024-06-30 | $100.00K 10-Q · filed 2024-11-14 | ||
| 2023-12-31 | $700.00K 10-K · filed 2025-04-08 | $700.00K 10-K · filed 2025-04-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |